Published in Immunology on January 01, 1977
Trypanosoma cruzi: in vitro induction of macrophage microbicidal activity. J Exp Med (1978) 4.29
Phagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated macrophages. Infect Immun (1978) 1.20
Thymus-dependent control of host defense mechanisms against Trypanosoma cruzi infection. Infect Immun (1979) 1.14
Cytotoxicity of human macrophages for tumor cells. Enhancement by human lymphocyte mediators. J Clin Invest (1979) 1.09
Isolation of the intracellular stage of Trypanosoma cruzi and its interaction with mouse macrophages in vitro. Infect Immun (1981) 0.87
Macrophage activation by cord factor (trehalose 6,6'-dimycolate): enhanced association with and intracellular killing of Trypanosoma cruzi. Infect Immun (1984) 0.85
Trypanosoma theileri: antibody-dependent killing by purified populations of bovine leucocytes. Clin Exp Immunol (1982) 0.85
Formation of complement subcomponent C1q-immunoglobulin G complex. Thermodynamic and chemical-modification studies. Biochem J (1982) 0.80
A human astrocytoma cell line is highly susceptible to infection with Trypanosoma cruzi. Mem Inst Oswaldo Cruz (2013) 0.78
Mammalian cellular culture models of Trypanosoma cruzi infection: a review of the published literature. Parasite (2014) 0.75
Alterations of macrophage functions by mediators from lymphocytes. J Exp Med (1971) 7.95
Effect of normal and activated human macrophages on Toxoplasma gondii. J Exp Med (1974) 4.39
Phagocytic and bacterial properties of normal human monocytes. J Clin Invest (1974) 2.65
Human monocytes and macrophages. Interaction with antigen and lymphocytes. J Cell Biol (1970) 2.35
Killing in vitro of Trypanosoma cruzi by macrophages from mice immunized with T. cruzi or BCG, and absence of cross-immunity on challege in vivo. J Exp Med (1975) 1.90
Studies of in vitro infection by Trypanosoma cruzi. I. Ultrastructural studies on the invasion of macrophages and L-cells. Am J Trop Med Hyg (1975) 1.74
Resistance of Trypanosoma cruzi to killing by macrophages. Nature (1975) 1.43
Trypanosoma cruzi: interaction with mouse peritoneal macrophages. Exp Parasitol (1972) 1.05
Enhancement of resistance and suppression of immunization against experimental Trypanosoma cruzi infection by Corynebacterium parvum. Infect Immun (1975) 1.05
Cellular immunity in vitro: migration inhibition and phagocytosis. Infect Immun (1971) 0.96
Multiplication of Trypanosoma (Schizotrypanum) cruzi in mouse peritoneal macrophages. Trans R Soc Trop Med Hyg (1971) 0.91
A vaccination procedure against Trypanosoma cruzi infection in mice by nonspecific immunization. J Immunol (1975) 0.86
Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science (1988) 7.96
Toxoplasmic encephalitis in AIDS. Clin Infect Dis (1992) 7.64
An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet (1997) 5.65
An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis. J Infect Dis (1980) 5.57
Failure to trigger the oxidative metabolic burst by normal macrophages: possible mechanism for survival of intracellular pathogens. J Exp Med (1980) 5.23
The compromised host and infection. II. Deep fungal infection. J Infect Dis (1969) 4.63
Effect of normal and activated human macrophages on Toxoplasma gondii. J Exp Med (1974) 4.39
AIDS commentary. Toxoplasmic encephalitis. J Infect Dis (1988) 4.14
Toxoplasmosis in pregnancy. Clin Infect Dis (1994) 3.91
Direct agglutination test for diagnosis of Toxoplasma infection: method for increasing sensitivity and specificity. J Clin Microbiol (1980) 3.81
In vitro induction of nonspecific resistance in macrophages by specifically sensitized lymphocytes. Infect Immun (1971) 3.81
Control of carcinogenesis: a possible role for the activated macrophage. Science (1972) 3.69
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science (1968) 3.65
Western Blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies. J Immunol (1983) 3.53
Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA (1984) 3.48
Studies on the mechanisms of resistance to phylogenetically diverse intracellular organisms. J Immunol (1969) 3.29
Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics (1980) 3.21
Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice. J Immunol (1989) 3.20
Pneumonia due to Chlamydia trachomatis in the immunocompromised (nude) mouse. J Infect Dis (1981) 3.19
An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. J Mol Biol (1996) 3.15
A role for activated macrophages in resistance to infection with Toxoplasma. Infect Immun (1972) 3.12
IgM antibodies in acute toxoplasmosis. II. Prevalence and significance in acquired cases. J Lab Clin Med (1968) 3.07
Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, Th1 lymphocyte clone. Reg Immunol (1994) 3.06
Cloning restriction fragments that promote expression of a gene in Bacillus subtilis. J Bacteriol (1981) 3.01
Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Exp Med (1996) 2.97
Toxoplasmosis in the compromised host. Ann Intern Med (1976) 2.96
False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test. J Clin Microbiol (1997) 2.84
Drug-induced aplastic anemia. Semin Hematol (1973) 2.81
Induction of resistance to Toxoplasma gondii in human macrophages by soluble lymphocyte products. J Immunol (1976) 2.79
The role of antibody in host defense against the agent of mouse pneumonitis. J Infect Dis (1982) 2.78
Dual regulation of resistance against Toxoplasma gondii infection by Lyt-2+ and Lyt-1+, L3T4+ T cells in mice. J Immunol (1988) 2.77
Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in pregnant women: experience in a US reference laboratory. J Infect Dis (2001) 2.74
Phagocytic and bacterial properties of normal human monocytes. J Clin Invest (1974) 2.65
Immunoglobulin M-immunosorbent agglutination assay for diagnosis of infectious diseases: diagnosis of acute congenital and acquired Toxoplasma infections. J Clin Microbiol (1981) 2.61
Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J Infect Dis (1971) 2.58
Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother (1991) 2.56
Toxoplasmosis: the time has come. N Engl J Med (1988) 2.54
Activity of recombinant tumor necrosis factor on Toxoplasma gondii and Trypanosoma cruzi. J Immunol (1986) 2.53
IgA antibodies for diagnosis of acute congenital and acquired toxoplasmosis. J Infect Dis (1990) 2.49
Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha. Infect Immun (1994) 2.48
The effect of anti-IFN-gamma antibody on the protective effect of Lyt-2+ immune T cells against toxoplasmosis in mice. J Immunol (1990) 2.47
The use of killed vaccines in immunization against an intracellular parasite: Toxoplasma gondii. J Immunol (1972) 2.46
Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG. J Infect Dis (1993) 2.45
Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance. Nat New Biol (1972) 2.44
Detection and characterization of membrane antigens of Toxoplasma gondii. J Immunol (1980) 2.43
Infectious complications after cardiac transplantation in man. Ann Intern Med (1971) 2.37
Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis (1982) 2.36
IgM antibodies in acute toxoplasmosis. I. Diagnostic significance in congenital cases and a method for their rapid demonstration. Pediatrics (1968) 2.36
Resistance against Cryptococcus conferred by intracellular bacteria and protozoa. J Infect Dis (1971) 2.34
Role for CD8+ T cells in antichlamydial immunity defined by Chlamydia-specific T-lymphocyte clones. Infect Immun (1994) 2.29
Cellular immunity to the mouse pneumonitis agent. J Infect Dis (1984) 2.28
Effect of murine interferon gamma on murine toxoplasmosis. J Infect Dis (1984) 2.27
Effect of gamma interferon on resolution of murine chlamydial genital infection. Infect Immun (1992) 2.24
Antigenemia in recently acquired acute toxoplasmosis. J Infect Dis (1980) 2.20
Differential agglutination test for diagnosis of recently acquired infection with Toxoplasma gondii. J Clin Microbiol (1990) 2.19
Nucleotide sequence of a Bacillus pumilus gene specifying chloramphenicol acetyltransferase. Gene (1983) 2.17
Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. Antimicrob Agents Chemother (1988) 2.16
Value of lymph-node biopsy in the diagnosis of acute acquired toxoplasmosis. N Engl J Med (1973) 2.15
Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother (1974) 2.14
Gamma-M-fluorescent treponemal antibody in the diagnosis of congenital syphilis. N Engl J Med (1969) 2.10
Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis (2001) 2.09
Toxoplasmosis in the adult--an overview. N Engl J Med (1978) 2.06
Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis (1996) 2.04
IgM enzyme-linked immunosorbent assay test for the diagnosis of congenital Toxoplasma infection. J Pediatr (1981) 2.04
Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis (1991) 2.04
Nocardial infections in the immunocompromised host: A detailed study in a defined population. Rev Infect Dis (1981) 2.03
Method for avoiding false-positive results occurring in immunoglobulin M enzyme-linked immunosorbent assays due to presence of both rheumatoid factor and antinuclear antibodies. J Clin Microbiol (1981) 2.03
Tropical fish aquariums. A source of Mycobacterium marinum infections resembling sporotrichosis. JAMA (1970) 2.00
In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol (1985) 2.00
Effect of tobacco and alcohol consumption on the Langerhans cell population of human lingual epithelium determined using a monoclonal antibody against HLADR. J Oral Pathol Med (1991) 2.00
Serologic diagnosis of acute lymphadenopathic toxoplasmosis. J Infect Dis (1980) 1.99
Chloramphenicol-inducible gene expression in Bacillus subtilis. Gene (1983) 1.96
Rapid prenatal diagnosis of congenital Toxoplasma infection by using polymerase chain reaction and amniotic fluid. J Clin Microbiol (1990) 1.95
Dissociation of effector functions in populations of activated macrophages. Nature (1977) 1.95
Analysis of Toxoplasma gondii antigens recognized by human sera obtained before and after acute infection. J Infect Dis (1986) 1.93
The RNA of toxoplasma gondii. Proc Soc Exp Biol Med (1970) 1.93
Synthetic polyanions protect mice against intracellular bacterial infection. Nature (1970) 1.92
Genetic control of murine resistance to Toxoplasma gondii. Infect Immun (1978) 1.91
Immunity and intracellular infection: resistance to bacteria in mice infected with a protozoan. Science (1968) 1.88
A method to evaluate the capacity of monocytes and macrophages to inhibit multiplication of an intracellular pathogen. J Immunol Methods (1979) 1.87
Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis (1992) 1.86
Hyperinsulinaemic hypoglycaemia in small for dates babies. Arch Dis Child (1990) 1.86
Opportunistic invasive fungal infections in patients with leukaemia lymphoma. Clin Haematol (1976) 1.86
Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group. J Clin Microbiol (1997) 1.85
Strain-dependent differences in murine susceptibility to toxoplasma. Infect Immun (1976) 1.85
False-positive anti-Toxoplasma fluorescent-antibody tests in patients with antinuclear antibodies. Appl Microbiol (1971) 1.85
Pulmonary infection in the compromised host: part I. Am Rev Respir Dis (1976) 1.82
The role of thymus-derived lymphocytes in the in vitro activation of macrophages to kill Listeria monocytogenes. J Immunol (1973) 1.82
The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo. Am J Trop Med Hyg (1979) 1.82
Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol (1981) 1.81
Toxoplasmosis in the non-AIDS immunocompromised host. Curr Clin Top Infect Dis (1993) 1.80
Outbreak of central-nervous-system toxoplasmosis in western Europe and North America. Lancet (1983) 1.80
Comparison of methods for quantitating antigen-specific immunoglobulin M antibody with a reverse enzyme-linked immunosorbent assay. J Clin Microbiol (1983) 1.79
Biology of Toxoplasma gondii. AIDS (1993) 1.79
Study of Abbott Toxo IMx system for detection of immunoglobulin G and immunoglobulin M toxoplasma antibodies: value of confirmatory testing for diagnosis of acute toxoplasmosis. J Clin Microbiol (1996) 1.78
Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis (1982) 1.77
Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis. Immunology (1995) 1.76